Cite
Pralsetinib and Sequential MET Inhibitors to Overcome MET Amplification Resistance in a Patient With a RET Fusion Driven Lung Cancer – Case Report
MLA
Pascal Wang, et al. “Pralsetinib and Sequential MET Inhibitors to Overcome MET Amplification Resistance in a Patient With a RET Fusion Driven Lung Cancer – Case Report.” Clinical Lung Cancer, vol. 23, Dec. 2022, pp. e568–72. EBSCOhost, https://doi.org/10.1016/j.cllc.2022.08.010.
APA
Pascal Wang, Lise Matton, Fatima Kebir, Khaldoun Kerrou, Antonin Dubois, Roger Lacave, Jacques Cadranel, & Vincent Fallet. (2022). Pralsetinib and Sequential MET Inhibitors to Overcome MET Amplification Resistance in a Patient With a RET Fusion Driven Lung Cancer – Case Report. Clinical Lung Cancer, 23, e568–e572. https://doi.org/10.1016/j.cllc.2022.08.010
Chicago
Pascal Wang, Lise Matton, Fatima Kebir, Khaldoun Kerrou, Antonin Dubois, Roger Lacave, Jacques Cadranel, and Vincent Fallet. 2022. “Pralsetinib and Sequential MET Inhibitors to Overcome MET Amplification Resistance in a Patient With a RET Fusion Driven Lung Cancer – Case Report.” Clinical Lung Cancer 23 (December): e568–72. doi:10.1016/j.cllc.2022.08.010.